A first-in-human, three-period crossover, double-blind, randomised, phase I study of CK 2127107 in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2015
At a glance
- Drugs CK 2127107 (Primary)
- Indications Muscular atrophy
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Astellas Pharma
- 19 Jun 2015 According to a Cytokinetics media release, results from this and two other studies (profiles 700242741 and 700247918) were presented at the 19th International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference.
- 13 Oct 2014 Status changed from active, no longer recruiting to completed, according to a Cytokinetics media release.
- 13 Oct 2014 Results published in the Media Release.